Palvella Therapeutics(PVLA)
$163.94-4.77 (-2.83%)
PVLA
Palvella Therapeutics stock forecast
$163.94
At close:-4.77 (-2.83%)
Want to see PVLA full AI Analyst Report?
Palvella Therapeutics (PVLA) Stock Forecast & Price Target
806 Followers
PVLA Analyst Ratings
Strong Buy
12Buy0Hold0Sell
Based on 12 analysts giving stock ratings to Palvella Therapeutics in the past 3 months
PVLA Stock 12 Month Forecast
Average Price Target
$230.92▲(40.85% Upside)Based on 12 Wall Street analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is $230.92 with a high forecast of $266.00 and a low forecast of $207.00. The average price target represents a 40.85% change from the last price of $163.94.
Past 12 Months12 Month ForecastJan2026Oct2026
High$266.00
Average$230.92
Low$207.00
Highest Price TargetHighest$266.00Average Price Target$230.92Lowest Price TargetLowest$207.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Whitney Ijem | Canaccord Genuity | $232→$243 | buy | 48.22%Upside | Reiterated | 11/09/26 | ||
| Andres Y. Maldonado | H.C. Wainwright | $246 | buy | 50.05%Upside | Reiterated | 11/06/26 | ||
| Trevor Allred | Oppenheimer | $210→$232 | buy | 41.52%Upside | Reiterated | 11/06/26 | ||
| Danielle Brill | Truist Financial | $207 | buy | 26.27%Upside | Reiterated | 11/06/26 | ||
| Albert Lowe | Craig-Hallum | $205→$230 | buy | 40.30%Upside | Reiterated | 11/06/26 | ||
| Ryan Deschner | Raymond James | $226→$230 | buy | 40.30%Upside | Reiterated | 11/06/26 | ||
| Jeet Mukherjee | BTIG | $215 | buy | 31.15%Upside | Reiterated | 11/05/26 | ||
| Graig Suvannavejh | Mizuho Securities | $240→$232 | buy | 41.52%Upside | Reiterated | 10/29/26 | ||
| Joshua Schimmer | Cantor Fitzgerald | $210 | buy | 28.10%Upside | Reiterated | 10/21/26 | ||
| Kaveri Pohlman | Clear Street | $220 | buy | 34.20%Upside | Reiterated | 10/20/26 | ||
| Alethia Young | William Blair | $266 | buy | 62.25%Upside | Initiated | 10/15/26 | ||
| Gautam Chukka | Chardan Capital | $240 | buy | 46.40%Upside | Reiterated | 09/21/26 | ||
| Sam Slutsky | LifeSci Capital | $225→$236 | buy | 43.96%Upside | Reiterated | 08/05/26 | ||
| Ritu Baral | TD Cowen | $267 | buy | 62.86%Upside | Reiterated | 08/04/26 | ||
| Annabel Samimy | Stifel Nicolaus | $250 | buy | 52.49%Upside | Reiterated | 06/24/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Whitney IjemCanaccord Genuity | BuyReiterated$232→$243 | 11/09/26 | 48.22%Upside | ||
| Andres Y. MaldonadoH.C. Wainwright | BuyReiterated$246 | 11/06/26 | 50.05%Upside | ||
| Trevor AllredOppenheimer | BuyReiterated$210→$232 | 11/06/26 | 41.52%Upside | ||
| Danielle BrillTruist Financial | BuyReiterated$207 | 11/06/26 | 26.27%Upside | ||
| Albert LoweCraig-Hallum | BuyReiterated$205→$230 | 11/06/26 | 40.30%Upside | ||
| Ryan DeschnerRaymond James | BuyReiterated$226→$230 | 11/06/26 | 40.30%Upside | ||
| Jeet MukherjeeBTIG | BuyReiterated$215 | 11/05/26 | 31.15%Upside | ||
| Graig SuvannavejhMizuho Securities | BuyReiterated$240→$232 | 10/29/26 | 41.52%Upside | ||
| Joshua SchimmerCantor Fitzgerald | BuyReiterated$210 | 10/21/26 | 28.10%Upside | ||
| Kaveri PohlmanClear Street | BuyReiterated$220 | 10/20/26 | 34.20%Upside | ||
| Alethia YoungWilliam Blair | BuyInitiated$266 | 10/15/26 | 62.25%Upside | ||
| Gautam ChukkaChardan Capital | BuyReiterated$240 | 09/21/26 | 46.40%Upside | ||
| Sam SlutskyLifeSci Capital | BuyReiterated$225→$236 | 08/05/26 | 43.96%Upside | ||
| Ritu BaralTD Cowen | BuyReiterated$267 | 08/04/26 | 62.86%Upside | ||
| Annabel SamimyStifel Nicolaus | BuyReiterated$250 | 06/24/26 | 52.49%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Palvella Therapeutics
3 Months
Success Rate8/9 ratings generated profit
89%
Average Return
+22.14%
Copying Graig Suvannavejh's trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +22.14% per trade.
1 Year
Success Rate7/7 ratings generated profit
100%
Average Return
+226.96%
Copying Joshua Schimmer's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +226.96% per trade.
2 Years
Success Rate16/16 ratings generated profit
100%
Average Return
+285.91%
Copying Whitney Ijem's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +285.91% per trade.
PVLA Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 28 | 17 | 13 | 13 | 9 |
| Buy | 2 | 5 | 5 | 5 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 30 | 22 | 18 | 18 | 17 |
In the current month, PVLA has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PVLA average Analyst price target in the past 3 months is 230.92.
PVLA Financial Forecast
High$-1.64
Consensus$-1.96
Low$-2.73
PVLA Earnings Forecast
Next quarter’s earnings estimate for PVLA is -$1.96 with a range of -$2.73 to -$1.64. The previous quarter’s EPS was -$1.70. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$0.00
Consensus$0.00
Low$0.00
PVLA Sales Forecast
Next quarter’s sales forecast for PVLA is $0 with a range of $0 to $0. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
PVLA Stock Forecast FAQ
What is PVLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Palvella Therapeutics’s 12-month average price target is $230.92.
What is PVLA’s upside potential, based on the analysts’ average price target?
Palvella Therapeutics has 40.85% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PVLA a Buy, Sell or Hold?
Palvella Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Palvella Therapeutics’s price target?
The average price target for Palvella Therapeutics is $230.92. This is based on 12 12-month price targets, issued in the past 3 months. The highest analyst price target is $266.00, the lowest forecast is $207.00. The average price target represents a 40.85% increase from the current price of $163.94.
What do analysts say about Palvella Therapeutics?
Palvella Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of PVLA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
